Form 6-K NYMOX PHARMACEUTICAL For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Nymox Pharma (NYMX) Reports Q3 Loss of $0.02/Share
November 14, 2014 10:44 AM ESTNymox Pharma (NASDAQ: NYMX) reported Q3 EPS of ($0.02), versus ($0.03) reported last year. Revenue for the quarter came in at $81.1 thousand, versus $88.9 thousand reported last year.
For earnings history and earnings-related data on Nymox Pharma (NYMX) click here.
... More


